Fairmount Funds Management LLC — 13F Holdings & Portfolio
CIK 1802528 · latest 13F-HR filed 2026-05-15
Fairmount Funds Management LLC manages $1.38B in 13F-reported U.S. long-equity assets across 12 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are DMRA (16.30%), DNTH (15.38%), COGT (15.30%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 1 new position, exited 2, added to 5, and trimmed 6.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$1.38B
Long-equity book
12
Distinct positions
2026-03-31
Filed 2026-05-15
+1 / −2 / ↑5 / ↓6
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- DIANTHUS THERAPEUTICS INC$124.8M +141.8%
- SPYRE THERAPEUTICS INC$71.0M +54.0%
- ORUKA THERAPEUTICS INC$69.4M +61.8%
- CRESCENT BIOPHARMA INC.$17.9M +54.9%
- ENLIVEN THERAPEUTICS INC$15.6M +27.3%
Top Trims
- APOGEE THERAPEUTICS INC-$129.5M -83.7%
- COGENT BIOSCIENCES INC-$108.0M -33.8%
- VIRIDIAN THERAPEUTICS INC-$45.3M -37.1%
- ZENAS BIOPHARMA INC-$34.1M -42.5%
- JADE BIOSCIENCES INC-$6.3M -8.9%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | DAMORA THERAPEUTICS INC | DMRA | 36322Q206 | $225.7M | 16.30% | 8,713,000 | SH |
| 2 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $212.9M | 15.38% | 2,537,191 | SH |
| 3 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $211.8M | 15.30% | 5,503,418 | SH |
| 4 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $202.7M | 14.64% | 4,018,101 | SH |
| 5 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $181.7M | 13.13% | 3,705,262 | SH |
| 6 | VIRIDIAN THERAPEUTICS INC | VRDN | 92790C104 | $76.6M | 5.53% | 3,914,458 | SH |
| 7 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $72.7M | 5.25% | 1,855,644 | SH |
| 8 | JADE BIOSCIENCES INC | JBIO | 008064206 | $64.0M | 4.62% | 4,553,494 | SH |
| 9 | CRESCENT BIOPHARMA INC. | CBIO | G2545C104 | $50.5M | 3.65% | 2,747,866 | SH |
| 10 | ZENAS BIOPHARMA INC | ZBIO | 98937L105 | $46.1M | 3.33% | 2,359,025 | SH |
| 11 | APOGEE THERAPEUTICS INC | APGE | 03770N101 | $25.1M | 1.82% | 298,647 | SH |
| 12 | INHIBIKASE THERAPEUTICS INC | IKT | 45719W205 | $14.5M | 1.05% | 8,625,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $1.38B | 12 | 0001104659-26-062419 |
| 2025-12-31 | 2026-02-17 | $1.31B | 13 | 0001104659-26-016303 |
| 2025-09-30 | 2025-11-14 | $1.11B | 17 | 0001104659-25-112427 |